Krystal Biotech: Beyond VYJUVEK Commercialization [Seeking Alpha]
Krystal Biotech, Inc. (KRYS)
Last krystal biotech, inc. earnings: 11/4 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.krystalbio.com/investors
Company Research
Source: Seeking Alpha
KRYS boasts 96% gross margins, nearly $1B in cash, and a platform poised to deliver four rare disease drugs by 2030. Recent positive Phase 1 data for KB407 in cystic fibrosis derisks inhaled delivery, enhancing confidence in upcoming AATD and NSCLC programs. With multiple pivotal readouts in 2026 and scalable operating leverage, KRYS offers substantial upside beyond the current Vyjuvek-driven valuation. Natali_Mis/iStock via Getty Images Last November , I reiterated my bullish stance on Krystal Biotech (NASDAQ: KRYS ) as commercialization of their topical gene therapy Vyjuvek expanded internationally in Europe and Japan . Vyjuvek treats Dystrophic Epidermolysis This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of KRYS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no
Show less
Read more
Impact Snapshot
Event Time:
KRYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRYS alerts
High impacting Krystal Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
KRYS
News
- Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Citigroup Inc. from $320.00 to $336.00. They now have a "buy" rating on the stock.MarketBeat
- Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Krystal Biotech (KRYS) Is Up 5.9% After Positive KB407 CF Gene Therapy Data And FDA Study Filing [Yahoo! Finance]Yahoo! Finance
- Assessing Krystal Biotech (KRYS) Valuation After Positive KB407 Cystic Fibrosis Trial Update [Yahoo! Finance]Yahoo! Finance
KRYS
Earnings
- 11/3/25 - Beat
KRYS
Sec Filings
- 1/12/26 - Form 8-K
- 1/8/26 - Form 8-K
- 12/23/25 - Form 8-K
- KRYS's page on the SEC website